ProLynx, based in San Francisco, CA, is a pioneering company that utilizes innovative technology to address the limitations of current drug conjugates for half-life extension. Their proven -eliminative drug delivery system enables controlled and sustained release of active drugs, peptides, proteins, and small molecules for extended periods, offering novel solutions for drug delivery.
With a focus on collaboration, ProLynx actively seeks partnerships with academia and pharmaceutical companies to develop and optimize drug conjugates for half-life extension. Their portfolio includes a range of pre-clinical and clinical candidates available for licensing, showcasing their commitment to advancing drug delivery technologies.
Generated from the website